Short answer
Charles River Laboratories (CRL) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 FY2026 results released August 5, 2026, covering the quarter ended June 27, 2026.
Charles River Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 FY2026 results released August 5, 2026, covering the quarter ended June 27, 2026
- Financial performance details contained in the attached press-release exhibit
- Forward-looking statements subject to identified risks in Charles River’s SEC filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $1.00B, down 2.7% YoY, while organic growth reached 0.1%, the strongest since Q3 2023
- Non-GAAP EPS $3.02, down 3.2% YoY, with margin pressured by higher DSA study costs and corporate expenses
- GAAP loss $(0.03) per share, reflecting a $63.7M divestiture loss, despite GAAP operating margin improving to 11.9%
- 2026 organic revenue guidance raised to 0.0%-1.0% and non-GAAP EPS to $11.15-$11.45
- $100M repurchase in Q2, with $700M remaining under the $1.0B authorization, supporting per-share results but increasing capital commitments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Charles River Laboratories 8-K filings
Get the next CRL 8-K as it lands
Follow CRL for push alerts, or ask the research agent what this filing means.